Yousif Capital Management LLC Trims Stake in Abbott Laboratories $ABT

Yousif Capital Management LLC trimmed its stake in Abbott Laboratories (NYSE:ABT) by 3.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 245,079 shares of the healthcare product maker’s stock after selling 7,493 shares during the period. Yousif Capital Management LLC’s holdings in Abbott Laboratories were worth $29,689,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Invesco Ltd. increased its stake in Abbott Laboratories by 51.0% in the 3rd quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock worth $1,868,718,000 after buying an additional 4,713,135 shares in the last quarter. Alliancebernstein L.P. increased its stake in Abbott Laboratories by 51.0% in the 3rd quarter. Alliancebernstein L.P. now owns 5,525,906 shares of the healthcare product maker’s stock worth $740,140,000 after buying an additional 1,865,250 shares in the last quarter. Capital International Investors boosted its holdings in shares of Abbott Laboratories by 2.5% during the 3rd quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker’s stock valued at $8,251,974,000 after purchasing an additional 1,478,076 shares during the last quarter. Danica Pension Livsforsikringsaktieselskab bought a new position in shares of Abbott Laboratories during the 3rd quarter valued at about $185,640,000. Finally, Credit Agricole S A bought a new position in shares of Abbott Laboratories during the 3rd quarter valued at about $175,044,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Abbott Laboratories Stock Down 0.5%

Shares of NYSE:ABT opened at $101.77 on Wednesday. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. Abbott Laboratories has a 12 month low of $100.88 and a 12 month high of $139.06. The company has a 50-day moving average price of $109.22 and a 200 day moving average price of $120.47. The company has a market cap of $177.25 billion, a price-to-earnings ratio of 27.36, a PEG ratio of 1.64 and a beta of 0.79.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The firm had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. During the same quarter last year, the firm earned $1.34 EPS. The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, equities research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.5%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.74%.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Piper Sandler dropped their price objective on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating for the company in a report on Friday, January 23rd. Freedom Capital raised shares of Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 29th. Raymond James Financial dropped their price objective on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Leerink Partners dropped their price objective on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a report on Friday, January 30th. Finally, Sanford C. Bernstein dropped their price objective on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $135.47.

Insider Transactions at Abbott Laboratories

In related news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $102,288.30. Following the completion of the transaction, the executive vice president owned 146,377 shares of the company’s stock, valued at approximately $16,918,253.66. This trade represents a 0.60% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP John A. Jr. Mccoy sold 585 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $67,614.30. Following the completion of the sale, the vice president directly owned 24,628 shares of the company’s stock, valued at approximately $2,846,504.24. The trade was a 2.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 3,055 shares of company stock worth $353,097 in the last quarter. Company insiders own 0.46% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.